The clinical implementation of a de-escalation strategy using CYP2C19 genotyping in patients with an acute coronary syndrome: insights from the FORCE-ACS registry

被引：0
|
作者：
Azzahhafi, J. [1 ]
Van den Broek, W. W. A. [1 ]
Yin, D. R. P. P. Chan Pin [1 ]
Ten Berg, J. M. [1 ]
机构：
[1] St Antonius Hosp, Nieuwegein, Netherlands
来源：
EUROPEAN HEART JOURNAL | 2023年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Difference in Impact of CYP2C19 Polymorphism on Platelet Reactivity and Clinical Outcomes Between Acute Coronary Syndrome (ACS) and Stable Angina
    Hokimoto, Seiji
    Akasaka, Tomonori
    Kaikita, Koichi
    Nakagawa, Kazuko
    Ogawa, Hisao
    CIRCULATION, 2013, 128 (22)
  • [22] Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention
    Johnson, Samuel G.
    Gruntowicz, Don
    Chua, Theresa
    Morlock, Robert J.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (07): : 552 - 557
  • [23] Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China
    Su, Qiang
    Li, Jian
    Tang, Zhili
    Yang, Siyun
    Xing, Guoqiang
    Liu, Tao
    Peng, Hong
    MEDICAL SCIENCE MONITOR, 2019, 25 : 7138 - 7148
  • [24] Is There Difference Impact of CYP2C19 Polymorphism on Platelet Reactivity and Adverse Clinical Events Between Acute Coronary Syndrome (ACS) and Stable Angina
    Hokimoto, Seiji
    Mizobe, Michio
    Nagano, Masahide
    Kaikita, Koici
    Nakagawa, Kazuko
    Ogawa, Hisao
    CIRCULATION, 2012, 126 (21)
  • [25] Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine" in Daily Clinical Practice
    Chan Pin Yin, Dean R. P. P.
    Vos, Gert-Jan A.
    van der Sangen, Niels M. R.
    Walhout, Ronald
    Tjon Joe Gin, R. Melvyn
    Nicastia, Deborah M.
    Langerveld, Jorina
    Claassens, Daniel M. F.
    Gimbel, Marieke E.
    Azzahhafi, Jaouad
    Bor, Willem L.
    Oirbans, Tom
    Dekker, Johan
    Vlachojannis, Georgios J.
    van Bommel, Rutger J.
    Appelman, Yolande
    Henriques, Jose P. S.
    Kikkert, Wouter J.
    ten Berg, Jurrien M.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 10
  • [26] The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome
    Kim, I-S
    Choi, B-R.
    Jeong, Y-H.
    Kwak, C. H.
    Kim, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (05) : 897 - 899
  • [27] CYP2C19 GENOTYPE-GUIDED ESCALATION AND DE-ESCALATION SWITCHING OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN A REAL-WORLD SETTING.
    Martin, J.
    Williams, A. K.
    Klein, M. D.
    Sriramoju, V. B.
    Madan, S.
    Rossi, J. S.
    Stouffer, G. A.
    Lee, C. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S23 - S24
  • [28] CYP2C19 GENOTYPE-GUIDED ESCALATION AND DE-ESCALATION SWITCHING OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN A REAL-WORLD SETTING.
    Martin, J.
    Williams, A. K.
    Klein, M. D.
    Sriramoju, V. B.
    Madan, S.
    Rossi, J. S.
    Stouffer, G. A.
    Lee, C. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S17 - S17
  • [29] CYP2C19 GENOTYPE-GUIDED ESCALATION AND DE-ESCALATION SWITCHING OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN A REAL-WORLD SETTING.
    Martin, J.
    Williams, A. K.
    Klein, M. D.
    Sriramoju, V. B.
    Madan, S.
    Rossi, J. S.
    Stouffer, G. A.
    Lee, C. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S120 - S120
  • [30] STUDY ON THE ASSOCIATION BETWEEN CLOPIDOGREL RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND CYP2C19 POLYMORPHISMS
    Geng, Wang Tian
    Heng, Cao
    HEART, 2011, 97 : A111 - A111
12345